Invention Grant
- Patent Title: Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
-
Application No.: US15559402Application Date: 2016-03-18
-
Publication No.: US11324822B2Publication Date: 2022-05-10
- Inventor: Robert Goodenow , Peter Ordentlich
- Applicant: Syndax Pharmaceuticals, Inc.
- Applicant Address: US MA Waltham
- Assignee: Syndax Pharmaceuticals, Inc.
- Current Assignee: Syndax Pharmaceuticals, Inc.
- Current Assignee Address: US MA Waltham
- Agency: Cooley LLP
- Agent Heidi A. Erlacher; Eric A. Owens
- International Application: PCT/US2016/023298 WO 20160318
- International Announcement: WO2016/154068 WO 20160929
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K31/4406 ; C07K16/28 ; A61K39/00
Abstract:
Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
Public/Granted literature
- US20180078639A1 COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER Public/Granted day:2018-03-22
Information query
